American Society of Hirudotherapy

H. yanyuanensis Progranulin (122-Cys Variant)

Distinctive progranulin paralog with 122 cysteine residues + nine tandem repeats in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025.

Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Distinctive progranulin paralog with 122 cysteine residues + nine tandem repeats in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025.
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

The 122-Cys progranulin paralog is documented at genome / structural level only; functional in vitro / in vivo characterization is pending. No FDA-approved derivative; H. yanyuanensis is not on the FDA K040187 cleared device species list.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Haemadipsa yanyuanensis
Discovered
2025 · Lin Y et al.
H. yanyuanensis Progranulin (122-Cys Variant) molecular structure

Biological Targets

  • progranulin-mediated tissue remodelling / wound-healing pathways (predicted)

Key Citations

  1. Lin Y et al. (2025), BMC Genomics · PMID 41469844

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.